Zhongyan Zhou
Zhongyan Zhou, Ph.D.
Associate Researcher · Graduate Supervisor
Central Laboratory & Cardiology Research Office, Longhua Hospital, Shanghai University of TCM

Biography

Ph.D. in Biomedical Sciences from University of Macau, Postdoctoral Fellow at the University of Hong Kong. Recipient of Shanghai Baiyulan Talent Program and Xinglin Young Scholar of Shanghai University of TCM. Long-term research on herbal medicine pharmacology and cardiovascular-metabolic diseases, with over 50 publications in journals including Pharmacological Research, Phytomedicine, Journal of Ethnopharmacology. Principal Investigator of 13 grants including National Natural Science Foundation of China.

Research

Herbal Efficacy & Active Compounds — Using multiple disease models (cells, zebrafish, mice, rats) to evaluate herbal efficacy, screen active compounds and elucidate mechanisms.
Cardiovascular & Metabolic Diseases — Herbal intervention and mechanistic studies on atherosclerosis, hypertension, hyperlipidemia, hyperhomocysteinemia, heart failure and obesity.
Cardio-oncology & Neurodegeneration — Protective effects and mechanisms of herbal medicine on cancer-related cardiotoxicity, neurodegenerative diseases and cerebral hemorrhage.
Vascular Biology & Coronary Microcirculation — Herbal regulation mechanisms on endothelial dysfunction, angiogenesis, inflammation, vascular senescence and coronary microcirculation dysfunction.
Circadian Rhythms & Diseases — Relationship between cardiovascular/metabolic circadian rhythm disorders and diseases, and herbal regulatory effects on circadian rhythms.

Open Positions

Prospective master/PhD students, postdocs and research assistants interested in herbal medicine pharmacology and cardiovascular-metabolic disease research are welcome to join our group.
Email: biozzy@126.com

About

Zhongyan Zhou

Zhongyan Zhou, Ph.D. Associate Researcher · Graduate Supervisor

Central Laboratory & Cardiology Research Office, Longhua Hospital, Shanghai University of TCM

Biography

Zhongyan Zhou, Ph.D. is Associate Researcher and Graduate Supervisor at Central Laboratory & Cardiology Research Office, Longhua Hospital, Shanghai University of Traditional Chinese Medicine. Recipient of Shanghai Baiyulan Talent Program and Xinglin Young Scholar Award.

His long-term research focuses on herbal medicine pharmacology and cardiovascular-metabolic diseases, using cells, zebrafish, mice, rats and other multiple disease models to conduct systematic studies of herbal efficacy and active compounds. Research areas cover cardiovascular & metabolic diseases (atherosclerosis, hypertension, hyperlipidemia, hyperhomocysteinemia, heart failure, obesity), cardio-oncology, neurodegenerative diseases, cerebral hemorrhage, endothelial dysfunction, angiogenesis, inflammation, vascular senescence, coronary microcirculation dysfunction, circadian rhythms & diseases, etc.

He has published 50 papers in international journals including Pharmacological Research, Free Radical Biology and Medicine, Acta Pharmacologica Sinica, Phytomedicine, Biomedicine & Pharmacotherapy, Journal of Ethnopharmacology. Among them, 27 papers as first author or corresponding author, including 20 SCI papers; among these, 1 paper with impact factor > 10, 14 papers with impact factor > 5, H-index 17. He has applied for 6 national invention patents.

Research Grants

Participated in more than 30 research projects at all levels; as the first person in charge, received funding for 13 projects, including NSFC General Program and Young Scientists Fund projects, Shanghai Science and Technology Commission Natural Science Foundation, Shanghai Health Commission research grants, etc.

Academic Service

Serves as reviewer for 20+ journals including Pharmacological Research, Phytomedicine, Biomedicine & Pharmacotherapy, Journal of Ethnopharmacology.

Talent Programs & Academic Awards

Academic Service & Review

Research

The group focuses on systematic studies of herbal efficacy and active compounds, comprehensively using cells, zebrafish, mice, rats and other multiple disease models, focusing on the field of cardiovascular & metabolic diseases, and extending to frontier areas such as cardio-oncology, neurodegenerative diseases, circadian rhythms & diseases, aiming to discover clinically translatable active compounds and mechanisms from traditional herbal medicine.

Research Directions

Herbal Efficacy & Active Compounds

Using multiple disease models (cells, zebrafish, mice, rats) to evaluate herbal efficacy, screen active compounds and elucidate mechanisms.

Cardiovascular & Metabolic Diseases

Herbal intervention and mechanistic studies on atherosclerosis, hypertension, hyperlipidemia, hyperhomocysteinemia, heart failure and obesity.

Cardio-oncology & Neurodegeneration

Protective effects and mechanisms of herbal medicine on cancer-related cardiotoxicity, neurodegenerative diseases and cerebral hemorrhage.

Vascular Biology & Coronary Microcirculation

Herbal regulation mechanisms on endothelial dysfunction, angiogenesis, inflammation, vascular senescence and coronary microcirculation dysfunction.

Circadian Rhythms & Diseases

Relationship between cardiovascular/metabolic circadian rhythm disorders and diseases, and herbal regulatory effects on circadian rhythms.

Disease Model Platforms

Cell Models

Vascular endothelial cells, smooth muscle cells, macrophages and other in vitro models for drug screening and mechanistic studies.

Zebrafish Models

Larval and adult zebrafish models for rapid screening of cardiovascular development, inflammation and lipid-lowering phenotypes.

Mouse Models

Genetically modified and high-fat diet-induced models for atherosclerosis and metabolic phenotype evaluation.

Rat Models

Hypertension, hyperlipidemia and other large animal models for efficacy evaluation and mechanism validation.

Publications

Herbal Medicine Promoting Angiogenesis, Anti-inflammation and Cardiovascular Disease Prevention

2024
From Microcirculation to Aging-Related Diseases: A Focus on Endothelial SIRT1
Law M, Wang PC, Zhou ZY*, Wang Y*. Pharmaceuticals, 2024, 17, 1495. (*corresponding author)
2024
Qiangxinyin formula protects against isoproterenol-induced cardiac hypertrophy
Zhou ZY#, Ma J#, Zhao WR#, Shi WT, Zhang J, Hu YY, Yue MY, Zhou WL, Yan H, Tang JY*, Wang Y*. Phytomedicine, 2024, 130:155717. (IF: 7.9, #co-first author)
2022
Tribulus terrestris L. extract ameliorates atherosclerosis by inhibition of vascular smooth muscle cell proliferation in ApoE-/- mice and A7r5 cells via suppression of Akt/MEK/ERK signaling
Zhang J#, Zhao WR#, Shi WT#, Tan JJ, Zhang KY, Tang JY, Chen XL*, Zhou ZY*. Journal of Ethnopharmacology, 2022, 297:115547. (*corresponding author)
2021
Tribulus terrestris L. Extract Protects against Lipopolysaccharide-Induced Inflammation in RAW 264.7 Macrophage and Zebrafish via Inhibition of Akt/MAPKs and NF-κB/iNOS-NO Signaling Pathways
Zhao WR#, Shi WT#, Zhang J#, Zhang KY, Qing Y, Tang JY, Chen XL*, Zhou ZY*. Evidence-based Complementary and Alternative Medicine, 2021, 2021:6628561. (*corresponding author)
2017
Spatholobi caulis extracts promote angiogenesis in HUVECs in vitro and in zebrafish embryos in vivo via up-regulation of VEGFRs
Zhou ZY#, Huan LY#, Zhao WR#, Tang N, Yu J*, Tang JY*. Journal of Ethnopharmacology, 2017, 200: 74-83. (#co-first author)
2016
Amelioration of acute myocardial infarction by saponins from flower buds of Panax notoginseng via pro-angiogenesis and anti-apoptosis
Yang BR, Cheung KK, Zhou X, Xie RF, Cheng PP, Wu S, Zhou ZY, Tang JY, Hoi PM, Wang YH, Lee SM. Journal of Ethnopharmacology, 2016, 181:50-8.

Herbal Medicine Improving Vascular Structure/Function and Metabolic Disease Prevention

2024
Intracellular Iron Deficiency and Abnormal Metabolism, Not Ferroptosis, Contributes to Homocysteine-Induced Vascular Endothelial Cell Death
Shi W#, Zhang J#, Zhao W#, Yue M, Ma J, Zeng S, Tang J, Wang Y*, Zhou Z*. Biomedicines, 2024, 12(10):2301. (*corresponding author)
2023
Lipocalin-2 promotes adipose-macrophage interactions to shape peripheral and central inflammatory responses in experimental autoimmune encephalomyelitis
Sciarretta F, Ceci V, Tiberi M, Zaccaria F, Li H, Zhou ZY, et al. Molecular Metabolism, 2023, 76:101783.
2023
Sodium tanshinone IIA sulfonate protects against hyperhomocysteine-induced vascular endothelial injury via activation of NNMT/SIRT1-mediated NRF2/HO-1 and AKT/MAPKs signaling in human umbilical vascular endothelial cells
Zhou ZY#, Shi WT#, Zhang J#, Zhao WR, Xiao Y, Zhang KY, Ma J, Tang JY*, Wang Y*. Biomedicine & Pharmacotherapy, 2023, 158:114137. (#co-first author)
2019
Pro-angiogenesis effect and transcriptome profile of Shuxinyin formula in zebrafish
Zhou ZY#, Xiao Y#, Zhao WR#, Zhang J, Shi WT, Ma ZL, Ye Q, Chen XL, Tang N*, Tang JY*. Phytomedicine, 2019, 65:153083. (#co-first author)
2019
Endothelial-Dependent and Independent Vascular Relaxation Effect of Tetrahydropalmatine on Rat Aorta
Zhou ZY#, Zhao WR#, Shi WT#, Xiao Y, Ma ZL, Xue JG, Zhang LQ, Ye Q, Chen XL*, Tang JY*. Frontiers in Pharmacology, 2019, 10:336. (#co-first author)
2017
Ferulic acid relaxed rat aortic, small mesenteric and coronary arteries by blocking voltage-gated calcium channel and calcium desensitization via dephosphorylation of ERK1/2 and MYPT1
Zhou ZY#, Xu JQ#, Zhao WR#, Chen XL, Jin Y, Tang N*, Tang JY*. European Journal of Pharmacology, 2017, 815: 26-32. (#co-first author)

Herbal Anti-tumor Effects and Cancer Therapy-induced Cardiotoxicity

2022
Targeting glycolysis in non-small cell lung cancer: Promises and challenges
Xu JQ#, Fu YL#, Zhang J#, Zhang KY, Ma J, Tang JY*, Zhang ZW*, Zhou ZY*. Frontiers in Pharmacology, 2022, 13:1037341. (*corresponding author)
2020
Antiangiogenesis effect of timosaponin AIII on HUVECs in vitro and zebrafish embryos in vivo
Zhou ZY#, Zhao WR#, Xiao Y#, Zhou XM, Huang C, Shi WT, Zhang J, Ye Q, Chen XL*, Tang JY*. Acta Pharmacologica Sinica, 2020, 41(2):260-269. (#co-first author)
2020
Pharmacological Activity, Pharmacokinetics, and Toxicity of Timosaponin AIII, a Natural Product Isolated From Anemarrhena asphodeloides Bunge: A Review
Lin Y#, Zhao WR#, Shi WT#, Zhang J, Zhang KY, Ding Q, Chen XL, Tang JY*, Zhou ZY*. Frontiers in Pharmacology, 2020, 11:764. (*corresponding author)
2021
Luteolin Prevents Cardiac Dysfunction and Improves the Chemotherapeutic Efficacy of Doxorubicin in Breast Cancer
Shi Y, Li F, Shen M, Sun C, Hao W, Wu C, Xie Y, Zhang S, Gao H, Yang J, Zhou Z, Gao D, Qin Y, Han X, Liu S. Frontiers in Cardiovascular Medicine, 2021, 8:750186.
2022
Osthole inhibits the migration and invasion of highly metastatic breast cancer cells by suppressing ITGα3/ITGβ5 signaling
Chen YQ, Song HY, Zhou ZY, Ma J, Luo ZY, Zhou Y, Wang JY, Liu S, Han XH. Acta Pharmacologica Sinica, 2022, 43(6):1544-1555.

Herbal Anti-cerebral Hemorrhage and Neurodegenerative Disease Prevention

2024
Exploring the causal link between serum amino acids and Parkinson's disease: a Mendelian randomization approach
Cheng L#, Yan J, Shi W, Zhang J, Dong Q, Hu Y, Zhou Z*, Ye Q*. Scientific Reports, 2024, 14(1): 30271. (*corresponding author)
2023
Identification of necroptosis-related genes in Parkinson's disease by integrated bioinformatics analysis and experimental validation
Lei C#, Zhongyan Z#, Wenting S, Jing Z, Liyun Q, Hongyi H, Juntao Y, Qing Y. Frontiers in Neuroscience, 2023, 17:1097293. (#co-first author)
2020
Mechanism Study of the Protective Effects of Sodium Tanshinone IIA Sulfonate Against Atorvastatin-Induced Cerebral Hemorrhage in Zebrafish: Transcriptome Analysis
Zhou ZY, Zhao WR, Xiao Y, Zhang J, Tang JY, Lee SM*. Frontiers in Pharmacology, 2020, 11:551745.
2018
Sodium tanshinone IIA sulfonate promotes endothelial integrity via regulating VE-cadherin dynamics and RhoA/ROCK-mediated cellular contractility and prevents atorvastatin-induced intracerebral hemorrhage in zebrafish
Zhou ZY#, Huang B#, Li S, Huang XH, Tang JY, Kwan YW, Hoi PM*, Lee SM*. Toxicology and Applied Pharmacology, 2018, 350:32-42. (#co-first author)
2018
Tanshinone I prevents atorvastatin-induced cerebral hemorrhage in zebrafish and stabilizes endothelial cell-cell adhesion by inhibiting VE-cadherin internalization and actin-myosin contractility
Huang B#, Zhou ZY#, Li S, Huang XH, Tang JY, Hoi MPM*, Lee SMY*. Pharmacological Research, 2018, 128: 389–398. (#co-first author, IF>10)
2015
Discovery of a novel neuroprotectant, BHDPC, that protects against MPP+/MPTP-induced neuronal death in multiple experimental models
Chong CM, Ma D, Zhao C, Franklin RJ, Zhou ZY, et al. Free Radical Biology and Medicine, 2015, 89:1057-66.
2015
Schisantherin A protects against 6-OHDA-induced dopaminergic neuron damage in zebrafish and cytotoxicity in SH-SY5Y cells through the ROS/NO and AKT/GSK3β pathways
Zhang LQ, Sa F, Chong CM, Wang Y, Zhou ZY, et al. Journal of Ethnopharmacology, 2015, 170:8-15.
2014
Discovery of a benzofuran derivative (MBPTA) as a novel ROCK inhibitor that protects against MPP⁺-induced oxidative stress and cell death in SH-SY5Y cells
Chong CM, Shen M, Zhou ZY, et al. Free Radical Biology and Medicine, 2014, 74:283-93.
2013
Danshensu protects against 6-hydroxydopamine-induced damage of PC12 cells in vitro and dopaminergic neurons in zebrafish
Chong CM#, Zhou ZY#, Razmovski-Naumovski V, et al. Neuroscience Letters, 2013, 543:121-125. (#co-first author)

Team

Wenting Shi

Wenting Shi

Assistant Researcher

Research: Herbal prevention and treatment of cardiovascular and cerebrovascular diseases

M.Sc. from Shanghai University of TCM, 12 publications (6 SCI papers as co-first author), 3 patents, PI of 3 projects including Shanghai Health Commission projects.

Yanyan Hu

Yanyan Hu

Research Assistant

Research: Herbal prevention and treatment of cardiovascular and cerebrovascular diseases (zebrafish microcirculation, cardiac function, behavior)

Graduated from Jinggangshan University, in charge of zebrafish model experiments.

Jing Zhang

Jing Zhang

Research Assistant

Research: Herbal prevention and treatment of cardiovascular diseases

M.Sc. from Shanghai University of TCM, 17 publications (7 as first author, 5 SCI), 2 patents, participated in national and provincial projects.

Contact

Contact Information

AffiliationLonghua Hospital, Shanghai University of Traditional Chinese Medicine
DepartmentCentral Laboratory & Cardiology Research Office
Emailbiozzy@126.com
Phone021-64385700 ext. 2521

Academic Profiles

ORCID0000-0002-2449-1380
ScopusAuthor ID: 56651293900
LoopFrontiers Loop Profile
Lab Homepage[TBD]
周忠焱
周忠焱 博士
副研究员 · 研究生导师
上海中医药大学附属龙华医院 中心实验室、心病研究室

个人简介

澳门大学生物医药博士，香港大学博士后，入选上海市白玉兰人才、上海中医药大学"杏林青年学者"。 长期从事中药药理与心血管代谢疾病研究，在 Pharmacological Research、Phytomedicine、 Journal of Ethnopharmacology 等期刊发表论文 50 余篇，主持国家自然科学基金等课题 13 项。

研究方向

中药有效性与有效成分研究 — 运用细胞、斑马鱼、小鼠、大鼠等多种疾病模型，开展中药有效性评价及有效成分筛选与作用机制研究。
心血管与代谢疾病 — 动脉粥样硬化、高血压、高脂血症、高同型半胱氨酸血症、心力衰竭和肥胖症等疾病的中药干预与机制研究。
心脏肿瘤学与神经退行性疾病 — 癌症相关心脏毒性、神经退行性疾病、脑出血等疾病的中药保护作用及机制研究。
血管生物学与冠脉微循环 — 内皮功能障碍、血管新生、炎症、血管衰老、冠脉微循环障碍等血管生物学问题的中药调控机制研究。
生物节律与疾病 — 心血管节律、代谢节律紊乱与疾病的关系，及中药的节律调控作用研究。

招生信息

欢迎对中药药理与心血管代谢疾病研究感兴趣的同学报考硕士/博士研究生，也欢迎博士后与科研助理加入课题组。
联系邮箱：biozzy@126.com

关于我

周忠焱

周忠焱 博士 副研究员 · 研究生导师

上海中医药大学附属龙华医院 中心实验室、心病研究室

个人简介

周忠焱博士，澳门大学生物医药博士，香港大学博士后。现任上海中医药大学附属龙华医院中心实验室、心病研究室副研究员，研究生导师。 入选上海市白玉兰人才、上海中医药大学"杏林青年学者"。

长期从事中药药理与心血管代谢疾病研究，运用细胞、斑马鱼、小鼠、大鼠等多种疾病模型，开展中药有效性及有效成分的系统研究。 研究领域涵盖心血管与代谢疾病（动脉粥样硬化、高血压、高脂血症、高同型半胱氨酸血症、心力衰竭、肥胖症）、 心脏肿瘤学、神经退行性疾病、脑出血、内皮功能障碍、血管新生、炎症、血管衰老、冠脉微循环障碍、生物节律与疾病等方向。

在 Pharmacological Research、Free Radical Biology and Medicine、Acta Pharmacologica Sinica、 Phytomedicine、Biomedicine & Pharmacotherapy、Journal of Ethnopharmacology 等国内外期刊发表论文 50 多篇。 其中以第一作者或通讯作者发表论文 27 篇，包括 SCI 论文 20 篇，其中影响因子大于 10 分 1 篇，影响因子大于 5 分 14 篇，H 因子 17。 申请国家发明专利 6 项。

科研项目

参与各级别课题研究 30 余项，其中以第一负责人获得课题资助 13 项，包括国家自然科学基金面上项目、青年项目， 上海市科委自然基金，上海市卫健委科研项目等。

学术服务

担任 Pharmacological Research、Phytomedicine、Biomedicine & Pharmacotherapy、 Journal of Ethnopharmacology 等 20 多个杂志的审稿专家。

人才计划与学术荣誉

学术兼职与评审服务

研究方向

课题组围绕中药有效性及有效成分开展系统研究，综合运用细胞、斑马鱼、小鼠、大鼠等多种疾病模型， 聚焦心血管与代谢疾病领域，并拓展至心脏肿瘤学、神经退行性疾病、生物节律与疾病等前沿方向， 旨在从传统中药中发掘具有临床转化价值的活性成分与作用机制。

研究方向

中药有效性与有效成分研究

运用细胞、斑马鱼、小鼠、大鼠等多种疾病模型，开展中药有效性评价及有效成分筛选与作用机制研究。

心血管与代谢疾病

动脉粥样硬化、高血压、高脂血症、高同型半胱氨酸血症、心力衰竭和肥胖症等疾病的中药干预与机制研究。

心脏肿瘤学与神经退行性疾病

癌症相关心脏毒性、神经退行性疾病、脑出血等疾病的中药保护作用及机制研究。

血管生物学与冠脉微循环

内皮功能障碍、血管新生、炎症、血管衰老、冠脉微循环障碍等血管生物学问题的中药调控机制研究。

生物节律与疾病

心血管节律、代谢节律紊乱与疾病的关系，及中药的节律调控作用研究。

疾病模型平台

细胞模型

血管内皮细胞、平滑肌细胞、巨噬细胞等体外模型，用于药物筛选与机制研究。

斑马鱼模型

幼鱼与成鱼模型，用于心血管发育、炎症与降脂相关表型的快速筛选。

小鼠模型

基因修饰与高脂饮食诱导等模型，用于动脉粥样硬化与代谢表型评价。

大鼠模型

高血压、高脂血症等大动物模型，用于药效评价与作用机制验证。

发表论文

中医药促进血管新生、抗炎及防治心血管疾病

2024
From Microcirculation to Aging-Related Diseases: A Focus on Endothelial SIRT1
Law M, Wang PC, Zhou ZY*, Wang Y*. Pharmaceuticals, 2024, 17, 1495. (*通讯作者)
2024
Qiangxinyin formula protects against isoproterenol-induced cardiac hypertrophy
Zhou ZY#, Ma J#, Zhao WR#, Shi WT, Zhang J, Hu YY, Yue MY, Zhou WL, Yan H, Tang JY*, Wang Y*. Phytomedicine, 2024, 130:155717. (IF: 7.9, #共同第一作者)
2022
Tribulus terrestris L. extract ameliorates atherosclerosis by inhibition of vascular smooth muscle cell proliferation in ApoE-/- mice and A7r5 cells via suppression of Akt/MEK/ERK signaling
Zhang J#, Zhao WR#, Shi WT#, Tan JJ, Zhang KY, Tang JY, Chen XL*, Zhou ZY*. Journal of Ethnopharmacology, 2022, 297:115547. (*通讯作者)
2021
Tribulus terrestris L. Extract Protects against Lipopolysaccharide-Induced Inflammation in RAW 264.7 Macrophage and Zebrafish via Inhibition of Akt/MAPKs and NF-κB/iNOS-NO Signaling Pathways
Zhao WR#, Shi WT#, Zhang J#, Zhang KY, Qing Y, Tang JY, Chen XL*, Zhou ZY*. Evidence-based Complementary and Alternative Medicine, 2021, 2021:6628561. (*通讯作者)
2017
Spatholobi caulis extracts promote angiogenesis in HUVECs in vitro and in zebrafish embryos in vivo via up-regulation of VEGFRs
Zhou ZY#, Huan LY#, Zhao WR#, Tang N, Yu J*, Tang JY*. Journal of Ethnopharmacology, 2017, 200: 74-83. (#共同第一作者)
2016
Amelioration of acute myocardial infarction by saponins from flower buds of Panax notoginseng via pro-angiogenesis and anti-apoptosis
Yang BR, Cheung KK, Zhou X, Xie RF, Cheng PP, Wu S, Zhou ZY, Tang JY, Hoi PM, Wang YH, Lee SM. Journal of Ethnopharmacology, 2016, 181:50-8.

中医药改善血管结构与功能及防治代谢性疾病

2024
Intracellular Iron Deficiency and Abnormal Metabolism, Not Ferroptosis, Contributes to Homocysteine-Induced Vascular Endothelial Cell Death
Shi W#, Zhang J#, Zhao W#, Yue M, Ma J, Zeng S, Tang J, Wang Y*, Zhou Z*. Biomedicines, 2024, 12(10):2301. (*通讯作者)
2023
Lipocalin-2 promotes adipose-macrophage interactions to shape peripheral and central inflammatory responses in experimental autoimmune encephalomyelitis
Sciarretta F, Ceci V, Tiberi M, Zaccaria F, Li H, Zhou ZY, et al. Molecular Metabolism, 2023, 76:101783.
2023
Sodium tanshinone IIA sulfonate protects against hyperhomocysteine-induced vascular endothelial injury via activation of NNMT/SIRT1-mediated NRF2/HO-1 and AKT/MAPKs signaling in human umbilical vascular endothelial cells
Zhou ZY#, Shi WT#, Zhang J#, Zhao WR, Xiao Y, Zhang KY, Ma J, Tang JY*, Wang Y*. Biomedicine & Pharmacotherapy, 2023, 158:114137. (#共同第一作者)
2019
Pro-angiogenesis effect and transcriptome profile of Shuxinyin formula in zebrafish
Zhou ZY#, Xiao Y#, Zhao WR#, Zhang J, Shi WT, Ma ZL, Ye Q, Chen XL, Tang N*, Tang JY*. Phytomedicine, 2019, 65:153083. (#共同第一作者)
2019
Endothelial-Dependent and Independent Vascular Relaxation Effect of Tetrahydropalmatine on Rat Aorta
Zhou ZY#, Zhao WR#, Shi WT#, Xiao Y, Ma ZL, Xue JG, Zhang LQ, Ye Q, Chen XL*, Tang JY*. Frontiers in Pharmacology, 2019, 10:336. (#共同第一作者)
2017
Ferulic acid relaxed rat aortic, small mesenteric and coronary arteries by blocking voltage-gated calcium channel and calcium desensitization via dephosphorylation of ERK1/2 and MYPT1
Zhou ZY#, Xu JQ#, Zhao WR#, Chen XL, Jin Y, Tang N*, Tang JY*. European Journal of Pharmacology, 2017, 815: 26-32. (#共同第一作者)

中医药抗肿瘤及肿瘤治疗引起的心血管毒性

2022
Targeting glycolysis in non-small cell lung cancer: Promises and challenges
Xu JQ#, Fu YL#, Zhang J#, Zhang KY, Ma J, Tang JY*, Zhang ZW*, Zhou ZY*. Frontiers in Pharmacology, 2022, 13:1037341. (*通讯作者)
2020
Antiangiogenesis effect of timosaponin AIII on HUVECs in vitro and zebrafish embryos in vivo
Zhou ZY#, Zhao WR#, Xiao Y#, Zhou XM, Huang C, Shi WT, Zhang J, Ye Q, Chen XL*, Tang JY*. Acta Pharmacologica Sinica, 2020, 41(2):260-269. (#共同第一作者)
2020
Pharmacological Activity, Pharmacokinetics, and Toxicity of Timosaponin AIII, a Natural Product Isolated From Anemarrhena asphodeloides Bunge: A Review
Lin Y#, Zhao WR#, Shi WT#, Zhang J, Zhang KY, Ding Q, Chen XL, Tang JY*, Zhou ZY*. Frontiers in Pharmacology, 2020, 11:764. (*通讯作者)
2021
Luteolin Prevents Cardiac Dysfunction and Improves the Chemotherapeutic Efficacy of Doxorubicin in Breast Cancer
Shi Y, Li F, Shen M, Sun C, Hao W, Wu C, Xie Y, Zhang S, Gao H, Yang J, Zhou Z, Gao D, Qin Y, Han X, Liu S. Frontiers in Cardiovascular Medicine, 2021, 8:750186.
2022
Osthole inhibits the migration and invasion of highly metastatic breast cancer cells by suppressing ITGα3/ITGβ5 signaling
Chen YQ, Song HY, Zhou ZY, Ma J, Luo ZY, Zhou Y, Wang JY, Liu S, Han XH. Acta Pharmacologica Sinica, 2022, 43(6):1544-1555.

中医药抗脑出血及防治神经退行性疾病

2024
Exploring the causal link between serum amino acids and Parkinson's disease: a Mendelian randomization approach
Cheng L#, Yan J, Shi W, Zhang J, Dong Q, Hu Y, Zhou Z*, Ye Q*. Scientific Reports, 2024, 14(1): 30271. (*通讯作者)
2023
Identification of necroptosis-related genes in Parkinson's disease by integrated bioinformatics analysis and experimental validation
Lei C#, Zhongyan Z#, Wenting S, Jing Z, Liyun Q, Hongyi H, Juntao Y, Qing Y. Frontiers in Neuroscience, 2023, 17:1097293. (#共同第一作者)
2020
Mechanism Study of the Protective Effects of Sodium Tanshinone IIA Sulfonate Against Atorvastatin-Induced Cerebral Hemorrhage in Zebrafish: Transcriptome Analysis
Zhou ZY, Zhao WR, Xiao Y, Zhang J, Tang JY, Lee SM*. Frontiers in Pharmacology, 2020, 11:551745.
2018
Sodium tanshinone IIA sulfonate promotes endothelial integrity via regulating VE-cadherin dynamics and RhoA/ROCK-mediated cellular contractility and prevents atorvastatin-induced intracerebral hemorrhage in zebrafish
Zhou ZY#, Huang B#, Li S, Huang XH, Tang JY, Kwan YW, Hoi PM*, Lee SM*. Toxicology and Applied Pharmacology, 2018, 350:32-42. (#共同第一作者)
2018
Tanshinone I prevents atorvastatin-induced cerebral hemorrhage in zebrafish and stabilizes endothelial cell-cell adhesion by inhibiting VE-cadherin internalization and actin-myosin contractility
Huang B#, Zhou ZY#, Li S, Huang XH, Tang JY, Hoi MPM*, Lee SMY*. Pharmacological Research, 2018, 128: 389–398. (#共同第一作者, IF>10)
2015
Discovery of a novel neuroprotectant, BHDPC, that protects against MPP+/MPTP-induced neuronal death in multiple experimental models
Chong CM, Ma D, Zhao C, Franklin RJ, Zhou ZY, et al. Free Radical Biology and Medicine, 2015, 89:1057-66.
2015
Schisantherin A protects against 6-OHDA-induced dopaminergic neuron damage in zebrafish and cytotoxicity in SH-SY5Y cells through the ROS/NO and AKT/GSK3β pathways
Zhang LQ, Sa F, Chong CM, Wang Y, Zhou ZY, et al. Journal of Ethnopharmacology, 2015, 170:8-15.
2014
Discovery of a benzofuran derivative (MBPTA) as a novel ROCK inhibitor that protects against MPP⁺-induced oxidative stress and cell death in SH-SY5Y cells
Chong CM, Shen M, Zhou ZY, et al. Free Radical Biology and Medicine, 2014, 74:283-93.
2013
Danshensu protects against 6-hydroxydopamine-induced damage of PC12 cells in vitro and dopaminergic neurons in zebrafish
Chong CM#, Zhou ZY#, Razmovski-Naumovski V, et al. Neuroscience Letters, 2013, 543:121-125. (#共同第一作者)

团队成员

施雯婷

施雯婷

助理研究员

研究方向：中医药防治心脑血管疾病

上海中医药大学硕士，发表论文12篇（共同一作SCI 6篇），申请专利3项，主持上海市卫健委课题等3项。

胡燕燕

胡燕燕

研究助理

研究方向：中医药防治心脑血管疾病（斑马鱼微循环、心功能、行为学）

毕业于井冈山大学，负责斑马鱼模型相关实验。

张静

张静

研究助理

研究方向：中医药防治心血管疾病

上海中医药大学硕士，发表论文17篇（一作7篇，SCI 5篇），申请专利2项，参与多项国家级及省部级课题。

联系我们

联系方式

单位上海中医药大学附属龙华医院
科室中心实验室、心病研究室
邮箱biozzy@126.com
电话021-64385700 转 2521

学术主页

ORCID0000-0002-2449-1380
ScopusAuthor ID: 56651293900
LoopFrontiers Loop Profile
课题组主页[待补充]